Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dennis Nemceff

Surgery Escondido, CA Medical Doctor

NPI 1427371228 CMS profile 109724

2130 Citracado Pkwy Ste 300, Escondido, CA 92029

Open in the dashboard

General payments

$36,832

340 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dennis Nemceff of Escondido, CA is reported in the CMS Open Payments database as having received $36,832 across 340 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,790 29
2024 General $7,672 42
2023 General $8,023 85
2022 General $8,020 76
2021 General $1,466 54
2020 General $1,845 28
2019 General $3,018 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dennis Nemceff
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Dennis Nemceff were reported at $6,790. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Dennis Nemceff Surgery median Middle half National median
2019 $3,018 $253 $82–$1,521 $163
2020 $1,845 $131 $40–$706 $114
2021 $1,466 $168 $50–$904 $132
2022 $8,020 $224 $76–$1,218 $149
2023 $8,023 $253 $82–$1,255 $160
2024 $7,672 $279 $90–$1,381 $164
2025 $6,790 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $24,382 9 payments
  2. Medtronic Vascular, Inc. $2,054 4 payments
  3. Medtronic, Inc. $1,727 50 payments
  4. Organogenesis Inc. $1,577 69 payments
  5. Musculoskeletal Transplant Foundation Inc. $1,565 7 payments
  6. Integra LifeSciences Corporation $935 9 payments
  7. Silk Road Medical, Inc. $891 18 payments
  8. Janssen Pharmaceuticals, Inc $470 27 payments
  9. Endologix, Inc. $321 3 payments
  10. Pfizer Inc. $228 10 payments
  11. Other $2,683 134 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $24,805 6 payments
  2. Food and Beverage $8,258 316 payments
  3. Grant $2,000 1 payment
  4. Travel and Lodging $1,383 11 payments
  5. Education $386 6 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $18,285 5 payments
  2. Auryon Laser System 100-120 Vac Cv $6,000 1 payment
  3. Endurant $2,038 3 payments
  4. Valiant Captivia $1,322 32 payments
  5. Puraply $1,030 43 payments
  6. Integra $863 7 payments
  7. ENROUTE 0.014 Guidewire $718 10 payments
  8. ENROUTE Transcarotid Stent System $718 10 payments
  9. ENROUTE Transcarotid Neuroprotection System $718 10 payments
  10. ENHANCE Transcarotid Peripheral Access Kit $718 10 payments
  11. Other $6,757 296 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

128

Median for Vascular Surgery: 122

Drug cost

$84,455

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 51 $52,029
Eliquis Apixaban Brand 29 $31,827
Clopidogrel Clopidogrel Bisulfate Brand 36 $450
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $149

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$110,893

Medicare's payments for the services billed

Medicare patients

110

Average age 75

Services billed

790

45 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 50%
Arthritis 47%
Chronic kidney disease 43%
Ischemic heart disease 35%
Heart failure 30%
Atrial fibrillation 30%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $36
$36 — —
Ozempic
  • Novo Nordisk Inc $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

340 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record